Background: Alterations in the expression of genes that control the cell cyde may be of critical importance in determining the sensitivity of cells and tumors to drugs (chemosensitivity) and radiation. Mutations and deletions of the p53 tumor suppressor gene in cell lines and tumors are associated with resistance to a variety of DNA-damaging agents. The effects of alterations in the cyclin genes and their products on drug action have not been studied. One of these genes, cyclin Dl, is expressed in early G! phase, and its protein product, together with the cyclin-dependent kinases CDK4 and CDK6, mediates the phosphorylation and functional inactivation of the retinoblastoma protein (pRb). Elevated levels of expression of cyclin Dl protein have been found in a variety of cancers, including breast cancer, head and neck cancer, non-small-cell lung cancer, and mantle cell lymphomas. Purpose: This study was conducted to investigate the effect of increased expression of cyclin Dl protein on the chemosensitivity profile of a human fibrosarcoma cell line. Methods: Expression plasmids containing either the neomycin-resistance gene and the complementary DNA sequence encoding human cyclin Dl or the neomycin-resistance gene only (control) were transfected by lipofection into the human HT1080 fibrosarcoma cell line, and cell colonies resistant to the antibiotic neomycin (G418) were isolated. Cyclin Dl messenger RNA (mRNA) and protein levels were measured by ribonuclease protection and western blot analyses, respectively. Dihydrofolate reductase (DHFR) mRNA and protein levels were measured by northern blot and western blot analyses, respectively. The phosphorylation status of pRb was assessed by western blot analysis. Cell cycle analysis was performed by use of the technique of fluorescence-activated cell sorting. Cytotoxicity assays were carried out by use of the sulforhodamine blue assay. Results: Of the 16 cyclin Dl-transfected cell clones that were isolated, four were randomly selected for further study. Two cell clones expressed high levels of cyclin Dl mRNA and protein as compared with control cells transfected with plasmids containing the neomycin-resistance gene only. A relative increase in the phosphorylated form of pRb in cells expressing high versus low levels of cyclin Dl was also revealed by western blot analysis. There was an increased fraction of cells in the S and G 2 phases of the cell cycle among cells expressing higher levels of cyclin Dl. Transfectants with increased cyclin Dl expression also had increased DHFR mRNA and protein expression. Cytotoxicity assays revealed a statistically significant (P<.01) increase in resistance to methotrexate in cells expressing high levels of cyclin Dl compared with cells expressing lower levels. There was no difference in resistance to doxorubicin, paclitaxel (Taxol), and cytarabine. Conclusion: Alterations in the expression of cyclin Dl led to altered cell cycle distribution in a human sarcoma cell line. The associated increase in DHFR expression resulted in increased resistance to methotrexate but had no effect on other classes of anticancer agents. Implications: These results indicate that alterations in cell cycle genes may differ in their effects on cytotoxicity. It will be important to determine the effects of alterations of other cell cycle regulatory genes on the responses of cells to specific classes of drugs. Tumors with overexpression of cyclin Dl may be relatively refractory to methotrexate treatment. [J Natl Cancer Inst 1996;88:1269-75]
The targets of action for many chemotherapeutic agents (such as the interaction of etoposide with the enzyme topoisomerase II and inhibition of dihydrofolate reductase [DHFR] by methotrexate) have been characterized. Alterations in the expression of the genes encoding these proteins may affect cellular chemosensitivity (12). The major target for methotrexate is the enzyme DHFR, which is important in the biosynthesis of RNA and DNA; drug treatment results in depletion of reduced cellular fo-late pools. Resistance to methotrexate in cell lines and tumors may result from such factors as decreased drug influx, increased hydrolysis of methotrexate, polyglutamylation of methotrexate, and amplification of the DHFR locus (1). However, it has also become apparent that the effect of drugs may be modulated to a major extent by alterations in expression of genes that control progression through the cell cycle. The most extensively studied of these genes is the p53 tumor suppressor gene (3, 4) . Cell lines and tumors that either fail to express or express mutated forms of the p53 protein show increased resistance to a wide range of chemotherapeutic agents of different classes and to irradiation. A crucial factor in this resistance seems to be the failure of these agents to induce cell cycle arrest in the absence of wild-type p53 (4) . Apart from p53 inactivation or deletion, other alterations in genes controlling the cell cycle may lead to changes in chemosensitivity. For example, mutations in the retinoblastoma protein (pRb) may result in the dissociation of the complex between pRb and the transcription factors E2F1, E2F2, and E2F3 and thereby cause an increase in DHFR transcription and resistance to methotrexate (5) .
Cyclin Dl is an important cell cycle regulatory protein that is expressed early in the G[ phase of the cell cycle. This protein, in association with the cyclin-dependent kinases CDK4 and CDK6, mediates the phosphorylation of pRb during Gi (6) . The effects of cyclin Dl on phosphorylation of pRb and the inability of anti-cyclin Dl antibodies to arrest growth of pRb-negative cells suggest that the key role of cyclin Dl may rest in its ability to functionally inactivate pRb (7) . Cyclin Dl has been shown to transform primary baby rat kidney cells in cooperation with overexpressed Ras protein (8) and with Myc protein in the induction of lymphomas in transgenic mice (9) . Alterations in the level of cyclin Dl, most commonly involving overexpression, have been found in a variety of human tumors, including breast cancer (10) and carcinomas of the head and neck (11), with chromosomal translocations leading to overexpression in one type of lymphoma (i.e., centrocytic or mantle cell lymphoma) (12) . Overexpression of cyclin Dl was found to be related to a poor prognosis in patients with head and neck cancer (13) .
As far as we can tell from the published literature, there has as yet been no report of the effects of changes in the level of cyclin Dl protein on cellular chemosensitivity. It would be expected that increased expression of the cyclin Dl protein would affect the phosphorylation state of pRb and therefore might lead to increased levels of free E2F proteins as a consequence of alterations in their interactions with pRb. These molecular events might consequently affect cellular methotrexate sensitivity as a result of increased E2F-mediated transcription of DHFR (14) .
In this study, we investigated alterations in cytotoxicity of several chemotherapeutic agents following transfection of cyclin Dl into a human fibrosarcoma cell line.
Materials and Methods

Cell Culture and Transfection
The human fibrosarcoma HT1080 cell line was obtained from the American Type Culture Collection (Rockville, MD). Cells were maintained in logarithmic phase growth in RPMI-1640 medium (Media Preparation Core Facility, Memorial Sloan-Kettering Cancer Center, New York, NY) supplemented with 10% fetal calf serum (Sigma Chemical Co., St. Louis, MO). Transfection was carried out by use of the synthetic cationic lipid N-( 1 -[2,3-<lioleoyloxy]propyl)-A'ys'//-trimethylammonium-methyl sulfate or DOTAP (Boehringer Mannheim Corp., Indianapolis, IN) method, according to the manufacturer's instructions. The cyclin D1-expressing plasmid, which also contains the neomycin-resistance gene (for selection), was a gift from Dr. A. Arnold (Massachusetts General Hospital, Boston) (6). Plasmid DNA (10 ug) was transfected into 10 7 cells. Stably transfected cells were selected by growth in the presence of the neomycin analogue G418 at 600 (ig/mL starting 48 hours after transfection. Resistant colonies were selected as single clones after 2 weeks of growth in the presence of G418 and were then expanded in 24-well plates for further analysis. Control transfections were carried out with the use of the Rc-CMV vector (Invitrogen, San Diego, CA) alone. Both control cell clones were pooled after growth for 2 weeks in 600 ug/mL G418.
Northern Blotting
For each sample, we prepared 30 |ig of total cellular RNA. Total cellular messenger RNA (mRNA) was prepared by use of the Ultraspec Method, as described in the manufacturer's instructions (Biotecx Laboratories, Houston, TX). Northern blotting and probing for DHFR were performed as described with the use of a human DHFR complementary DNA (cDNA) probe (pKT7-HDR) (15) . A probe for the human acidic ribosomal phosphoprotein 36B4 cDNA was used as a loading control (16) ; the 36B4 gene is in widespread use as a control for northern blotting (17, 18) and does not appear to be cell cycle transcnptionally regulated. Probes were prepared by random priming using [a-
32 P]deoxycytidine triphosphate (Amersham Life Science, Inc., Arlington Heights, IL) as described (19) . Quantitation of the northern blot was performed by densitometry using a gel scanner (1312 V A-5 Absorbance Detector, ISCO, Lincoln, NE).
Ribonuclease Protection
Ribonuclease (RNase) protection was carried out as described (20) with the use of a 440-base-pair EcoRl/Pst I restriction fragment (corresponding to nucleotide positions +1 to +440 of the coding sequence) of the human cyclin Dl cDNA hybridized with total cellular mRNA. A riboprobe for 36B4 was used as a control for mRNA loading. Following addition of 0.5 |ig template to 10 mM dithiothreitol (DTT), 0.4 mM adenosine, guanosine, and thymidine triphosphates, 5 nL [an P]cytosine triphosphate (Amersham Life Science, Inc.), 40 U RNasin, and 40 U T3 RNA polymerase (Boehringer Mannheim Corp.) in a total volume of 20 ui-, the mixture was incubated at 37 'C for 30 minutes. Then 35 U of deoxyribonuclease I was added, and the sample was incubated for an additional 15 minutes at 37 *C. The sample was then spun through a G50 Sephadex column (Boehringer Mannheim Corp.) to remove unincorporated nucleotides. Approximately 0.5 x 10 6 cpm were added to 20 |ig total mRNA, and the mixture was incubated for 16 hours at 55 "C. Following hybridization, RNA-RNA hybrids were digested for 30 minutes at 30 *C in a solution containing 40 (ig/mL RNase A and 2 |ig/mL RNase Tl (Boehringer Mannheim Corp.). Reaction mixtures were ethanol precipitated, resuspended in gel loading buffer, and run on a 6% polyacrylamide DNA-sequencing gel. The gel was then dried down and exposed to x-ray film (Fuji Film, Tokyo, Japan). The blot was quantitated by use of a Betascope 603 Blot Analyzer (Betagen, Waltham, MA).
Western Blotting
The monoclonal antibody for cyclin Dl was obtained from Santa Cruz Biotechnology, Santa Cruz, CA (catalog No. sc-246). The antibody for pRb was obtained from Pharmingen, San Diego, CA (catalog No. 14001A). The polyclonal antibody for DHFR was a gift of Dr. B. Dolnick (Roswell Park Cancer Institute, Buffalo, NY). Whole-cell extracts were prepared according to the manufacturer's instructions (Santa Cruz Biotechnology). Protein concentrations in these extracts were estimated by the Bradford assay (21). Immunoblots were prepared according to the manufacturer's instructions (Santa Cruz Biotechnology). Protein extracts (100 |ig) were boiled for 5 minutes in the presence of sample buffer consisting of 2% sodium dodecyl sulfate (SDS), 10 nW DTT, 60 mM Tris (pH 6.8), and 0.01% bromophenol blue and then loaded onto and electrophoresed in 15% polyacrylamide-SDS gels, with the exception of pRb for which a 7% gel was used. Protein loading was visualized by Ponceau S staining (22) . Nitrocellulose membranes (Optitran; Schleicher and Schuell, Inc., Keene, NH) were incubated with the enhanced chemiluminescence system according to the manufacturer's instructions (Amersham, Buckinghamshire, U.K.) and ex-posed to film. Densitometry was performed by use of the 1312 VA-5 Absorbance Detector gel scanner.
Analysis by Fluorescence-Activated Cell Sorting (FACS)
The DNA content of cells was determined by flow cytometry. Cells in exponential growth phase-were harvested, fixed with methanol at 4 "C, and stained with propidium iodide (Sigma Chemical Co.) (0.2 mg/mL plus 1 ng/mL RNase A in phosphate-buffered saline). The DNA content was then determined as 620 nm fluorescence by use of a fluorescence-activated cell sorter (Becton Dickinson, San Jose, CA). Data were analyzed with the Multicycle Program (Phoenix Flow Systems, San Diego, CA).
Cytotoxicity
Methotrexate (Rheumatrex) was obtained from Lederle Laboratories, Pearl River, NY. Doxorubicin (Adriamycin) was obtained from Sigma Chemical Co. Paclitaxel (Taxol) was obtained from Bristol-Myers Squibb, Princeton, NJ. Cytarabine (Cytosar-U) was obtained from Upjohn Co., Kalamazoo, MI. Assays were carried out with the use of the sulforhodamine blue assay (Sigma Chemical Co.) as described (23) . Cells were seeded into 96-well plates and incubated with methotrexate for % hours before assay. Experiments were repeated three times in duplicate. Exposure to cytarabine, paclitaxel, and doxorubicin was for 24 hours with a further 72 hours of growth in drug-free medium. These experiments were repeated twice in duplicate. For methotrexate assays, cells were incubated in RPMI-1640 medium with 10% dialyzed fetal calf serum. The range of concentrations used was as follows: methotrexate, 10"* M to 10" 9 M; paclitaxel. Iff" 4 M to 10"" M\ doxorubicin, 10"** M to 10"'° M; and cytarabine, 10" 3 M to 10"'° M. ICy, was determined as the concentration of drug inhibiting cell growth by 50% as measured by the sulforhodamine blue assay.
Statistical Analysis
Data were subjected to Wilcoxon's rank sum analysis to determine the significance of cyclin Dl expression at specific drug concentrations. All P values resulted from two-sided statistical tests. 
Results
Transfection of Cyclin Dl cDNA and Measurement of Its Expression
An expression plasmid containing the neomycin-resistance gene and the human cyclin Dl cDNA was transfected into die human HT1080 fibrosarcoma cell line by use of the DOTAP method. Following selection with G418, 16 cell clones were isolated; four were randomly selected and further analyzed. The control cell clones that had been transfected widi the neomycinresistance (Rc-CMV) vector were pooled. Thus, we were able to compare the properties of the pooled-vector-only cell clones with the cell clones that had been transfected with the expression vector plasmid containing not only the neomycin-resistance gene but also the human cyclin Dl cDNA. Two of these cell clones (clones 14 and 16) expressed high levels of cyclin Dl mRNA (as demonstrated by RNase protection), whereas two others expressed levels of cyclin Dl (clones 7 and 12) at the same level as that of the control clone transfected with vector alone (Fig. 1, A) . Measurement of the relative expression of cyclin Dl mRNA by phosphoimaging revealed ratios of 2.17 (clone 7), 0.48 (clone 12), 14.4 (clone 14), and 10.8 (clone 16) as compared with the vector-only-transfected control in this experiment. Western blot analyses of these transfectants confirmed higher levels of cyclin Dl protein in clones 14 and 16 in three separate experiments (Fig. 1, B) . The ratios of cyclin Dl expression as measured by densitometry were 0.90 (clone 7), 0.70 (clone 12), 2.86 (clone 14), and 2.77 (clone 16) as compared wim the vector-only-transfected control. The discrepancy between the relatively higher expression of cyclin Dl mRNA than protein is probably due to post-transcriptional regulation.
Expression of cyclin Dl was also confirmed by immunohistochemistry in which high levels of nuclear expression were seen in clones 14 and 16 (data not shown). Morphologically, cells expressing high levels of cyclin Dl were indistinguishable from parental cells. Doubling times of vector-only, low-cyclin Dl, and high-cyclin Dl transfectants were unchanged from the doubling time of parental cells at 26 hours.
FACS Analysis of Cell Cycle Distributions in Various Cell Populations
FACS analysis of exponentially growing transfectants was performed to determine the relative proportions of cells at different points in the cell cycle. The results from four transfected clones are shown in Fig. 2 . There was a substantial reduction in the proportion of cells in Gi, but there was a corresponding increase in the fraction of cells in S and G 2 among cells expressing high levels of cyclin Dl (clones 14 and 16) compared with the parental cells, neo-only transfectants, and transfectants with low cyclin Dl expression (clones 7 and 12). This result is consistent with that of a study in Rat-1 fibroblasts (24) demonstrating that overexpression of cyclin Dl increased the percentage of cells in S phase without altering the length of the cell cycle. 
Measurement of DHFR Expression
A previous study {14) showed activation of the DHFR promoter following in vitro transient transfection of the cyclin Dl-coding sequence. Increased transcription of E2F-inducible genes with increased cyclin Dl expression has yet to be demonstrated. To determine whether expression of cyclin Dl affected the level of expression of gene targets of chemotherapeutic agents, we measured the expression of DHFR by northern blot hybridization analysis. Clones expressing higher levels of cyclin Dl (clones 14 and 16) expressed higher levels of DHFR mRNA than clones expressing low levels of cyclin Dl (clones 7 and 12) (Fig. 3, A) . The ratios of expression as measured by densitometry in this experiment were 1.1 (clone 7), 1.0 (clone 12), 2.23 (clone 14), and 2.45 (clone 16).
Western blotting with the use of a polyclonal rabbit antibody confirmed a higher level of DHFR protein expression in transfectants with high levels of cyclin Dl (clones 14 and 16) (Fig. 3,  B) . Densitometry of the western blots revealed a greater than twofold increase in DHFR expression in clones 14 and 16 compared with clones 7 and 12; ratios of 0.9 (clone 7), 0.61 (clone 
Measurement of pRb Expression and Phosphorylation
In view of the probable effect of cyclin Dl on phosphorylation of pRb and E2F-mediated DHFR transcription, western blot analyses were carried out on cell lysates from the transfected clones with a monoclonal antibody to pRb. An increase in the ratio of the upper band representing phosphorylated pRb was seen with extracts from transfectants expressing high levels of cyclin Dl (clones 14 and 16) as compared with clones expressing low levels of cyclin Dl (clones 7 and 12) (Fig. 4) . This finding is consistent with the observation that cells that overexpress cyclin D1 had an increase in the number of cells in the S and G 2 phases.
Methotrexate Sensitivity of Transfected Clones
Cytotoxicity assays were carried out on cyclin Dl transfectants by use of the sulforhodamine blue assay. Methotrexate, paclitaxel, cytarabine, and doxorubicin were used in these experiments. There was a marked increase in the IC50 values for methotrexate resistance in cells expressing high levels of cyclin Dl (Fig. 5) There was a statistically significant difference in methotrexate resistance between clones expressing low levels of cyclin Dl (clones 7 and 12) and high levels of cyclin Dl (clones 14 and 16) (P<.01). This was associated with a twofold increase in DHFR protein as ascertained by western blot analysis. The cytotoxic effect of methotrexate was the same regardless of whether cells were exposed to drug for 24 or 96 hours. For assessment of the chemosensitivity to paclitaxel, cytarabine, and doxorubicin, cells were incubated with drug for 24 hours and subsequently grown for 72 hours in drug-free culture medium (Table 1 ). The chemosensitivity did not differ significantly between low (clones 7 and 12) and high (clones 14 and 16) cyclin Dl expressers with respect to paclitaxel (P>.08), cytarabine (P>.2), and doxorubicin (P>.\) when comparisons were made by Wilcoxon's rank sum analysis at several dose levels.
Discussion
This study demonstrates that alterations in the cellular levels of cyclin Dl, which occur in a variety of tumor types, may be associated with changes in cell cycle distribution and in the sensitivity of the cells to methotrexate. This increased drug resistance is specific for methotrexate and is associated with an increase in the expression of DHFR. Consequently, there is an increase in resistance to methotrexate, a commonly used antimetabolite. The increase in the S-phase fraction does not affect the response to such chemotherapeutic agents as paclitaxel and cytarabine. This result is consistent with the result obtained from studies on a panel of human sarcoma cell lines that demonstrated that mutation or deletion of pRb causes increased DHFR expression with consequent increased cellular resistance to methotrexate (5) . Transfection of an expression plasmid for pRb resulted in increased sensitivity to methotrexate. Furthermore, rodent fibroblasts with deleted pRb showed a twofold to threefold increase in DHFR protein expression as compared with fibroblasts *iC x was determined as the concentration of drug inhibiting cell growth by 50% as measured by sulforhodamine blue assay. tCells were exposed to drug for 24 hours and, after washing with phosphate-buffered saline, were incubated in drug-free medium for a further 72 hours. Experiments were repeated twice in duplicate.
$Lowcyclin Dl expression. §High cyclin Dl expression.
expressing pRb (25) . Thus, alterations in genes that increase the proportion of cells in the S and G 2 phases of the cell cycle may affect chemosensitivity to methotrexate. The effect of cyclin Dl overexpression seems to be mediated through the increased phosphorylation of pRb. The interdependence of cyclin Dl and pRb has been shown in studies in which there is a reduction of cyclin Dl-cdk4 and cdk6 complexes in cell lines lacking functional pRb (26) . Similarly, although the injection of cyclin Dl antibodies in the early to middle G| phase causes arrest before entry into S phase, this arrest does not occur when the cell line contains pRb that is either mutated or inactivated by expression of tumor virus protein (27) .
The cyclin Dl-induced increase in DHFR transcription is consistent with the finding that transient transfection of cyclin Dl in NIH3T3 cells induced expression of a DHFR promoter construct (14) . Cyclin Dl overexpression was also shown to stimulate E2F-dependent transcription in a co-transfection assay with the E2 promoter in 3T3 cells (1428). Although five E2F genes have thus far been identified, it is not known which gene product acts on the DHFR promoter.
Several different effects of cyclin Dl overexpression have been reported. Overexpression of cyclin Dl in rodent fibroblasts reduced the duration of the G) phase by several hours and reduced the serum requirements of the transfected cells (24, 29) . Studies in skeletal myoblasts in which cyclin Dl levels were elevated by transfection of a cDNA coding for the cyclin Dl gene resulted in inhibition of differentiation (30) . In contrast, endogenously or exogenously induced cyclin Dl overexpression resulted in a block to proliferation and S-phase entry in normal diploid fibroblasts (31), a reduced growth rate in the human mammary epithelial cell line (HBL-100) (32) , and cell cycle arrest in a megakaryocytic cell line (33) . The decreased growth rate found in the mammary cell line was associated with a prolongation of S phase. It is interesting that expression of an antisense cyclin Dl construct in human esophageaJ cells resulted in regression of the transformed phenotype (34) . Thus, the phenotype of cyclin Dl overexpression may depend on the cellular context. It is possible that overexpression of cyclin Dl confers an additional proliferative advantage to transformed cells.
In head and neck cancer, cyclin Dl protein levels have been found to be a prognostic marker of disease outcome (13) . Because methotrexate is frequently used to treat these cancers, a study of tumor response to this drug in relation to cyclin Dl status is warranted. It is possible that elevated levels of DHFR found in tumors with increased levels of cyclin Dl might result in intrinsic resistance to methotrexate. Furthermore, alterations of other cell cycle genes found in tumors (35) may also affect responses to chemotherapeutic agents by effects on the proportion of cells in different phases of the cell cycle. These studies should help to clarify the link between perturbations of cell cycle genes in cancer cells and the expression of specific targets for drug action.
